{"prompt": "['IRB Approved', '9984', 'Document Release Date: 03/25/2021', 'Clinical Study Protocol', 'Drug Substance Olaparib (AZD2281, KU-0059436); Testosterone', 'Consortium Study Number 9984', 'Edition Number 1.6', 'Date February 24, 2021', 'LIST OF TABLES', 'Table 1', 'Adverse Drug Reactions reported in Clinical Trials', '24', 'Table 2', 'Volume of Blood to Be Drawn From Each Subject', '52', 'Table 3', 'Management of anemia', '58', 'Table 4', 'Management of neutropenia, leukopenia and thrombocytopenia', '59', 'Table 5', 'Dose reductions for olaparib treatment', '61', 'LIST OF FIGURES', 'Figure 1', 'Clinical states of prostate cancer', '10', 'Figure 2', 'Timeline of recent Food and Drug Administration (FDA) approval for', 'mCRPC drugs', '11', 'Figure 3', 'Growth inhibitory effects of supraphysiologic androgens', '13', 'Figure 4', 'Supraphysiologic androgens induce dsDNA breaks in prostate', 'cancer cells', '13', 'Figure 5.', 'PSA responses and Quality of Life changes following BAT', '15', 'Figure 6', 'Adverse events observed in trials testing BAT in men with advanced', 'prostate cancer', '15', 'Figure 7', 'DDR alterations and percent change in PSA in men receiving BAT', '16', 'Figure 8', 'Graphical plot of olaparib activity (IC50) across the KU95 cell', 'line panel', '18', 'Figure 9', 'Graphical plot of olaparib sensitive cell lines (IC50 <M) arranged by', 'known BRCA1/2 mutation status or low expression of HRR genes', '19', 'Figure 10', 'Results from the Phase II TOPARP Trial', '22', 'Figure 11', 'Study schematic', '35', 'Figure 12', 'Modeled T Kinetics with different T enanthate dosing schedules', '55', '6(93)', 'Printed on 3/25/202']['IRB Approved', '9984', 'Document Release Date: 03/25/2021', 'Clinical Study Protocol', 'Drug Substance Olaparib (AZD2281, KU-0059436); Testosterone', 'Consortium Study Number 9984', 'Edition Number 1.6', 'Date February 24, 2021', 'LIST OF ABBREVIATIONS AND DEFINITION OF TERMS', 'The following abbreviations and special terms are used in this Clinical Study Protocol.', 'Abbreviation or', 'Explanation', 'special term', 'ADT', 'Androgen deprivation therapy', 'AE', 'adverse event', 'AESI', 'adverse event of special interest', 'ALP', 'alkaline phosphatase', 'ALT', 'alanine aminotransferase', 'AR', 'Androgen receptor', 'AST', 'aspartate aminotransferase', 'AUC', 'area under the concentration-time curve', 'BAT', 'Bipolar Androgen Therapy', 'BD/BID', 'Twice daily', 'CI', 'confidence interval', 'CL', 'clearance', 'Cmax', 'peak concentration', 'Cmax,ss', 'peak concentration at steady state', 'Cmin', 'trough concentration', 'Cmin,ss', 'trough concentration at steady state', 'CNS', 'central nervous system', 'CR', 'complete response', 'CRPC', 'Castration-resistant prostate cancer', 'CT', 'computed tomography', 'CTC', 'circulating tumor cell', 'ctDNA', 'cell-free tumor DNA', 'DDR', 'DNA Damage Repair', 'DHEA-S', 'Dehydroepiandrosterone sulfate', 'DHT', 'Dihydrotestosterone', 'DLT', 'dose-limiting toxicity', 'DNA', 'deoxyribonucleic acid', '7(93)', 'Printed on 3/25/202']['IRB Approved', '9984', 'Document Release Date: 03/25/2021', 'Clinical Study Protocol', 'Drug Substance Olaparib (AZD2281, KU-0059436); Testosterone', 'Consortium Study Number 9984', 'Edition Number 1.6', 'Date February 24, 2021', 'Abbreviation or', 'Explanation', 'special term', 'DSB', 'Double strand DNA break', 'ECG', 'electrocardiogram', 'ECOG', 'Eastern Cooperative Oncology Group', 'EDTA', 'disodium edetate dihydrate', 'FFPE', 'formalin fixed paraffin embedded', 'GCP', 'Good Clinical Practice', 'GMP', 'Good Manufacturing Practice', 'GLP', 'Good Laboratory Practice', 'HR/HRR', 'Homologous recombination/Homologous Recombination Repair', 'HRD', 'Homologous recombination deficiency', 'ICF', 'informed consent form', 'ICH', 'International Conference on Harmonization', 'IF', 'Immunofluorescence', 'IHC', 'immunohistochemistry', 'IRB', 'Institutional Review Board', 'IV', 'intravenous(ly)', 'LHRH', 'luteinizing hormone releasing hormone', 'mCRPC', 'metastatic castration-resistant prostate cancer', 'MRI', 'magnetic resonance imaging', 'mRNA', 'messenger ribonucleic acid', 'MTD', 'maximum tolerated dose', 'NCICTCAE', 'National Cancer Institute Common Terminology Criteria for Adverse', 'Events', 'NHEJ', 'Non-homologous end-joining', 'OR', 'objective response', 'ORR', 'objective response rate', 'os', 'overall survival', 'PC', 'Prostate cancer', 'PCWG', 'Prostate Cancer Working Group', 'PFS', 'progression-free survival', 'PK', 'pharmacokinetic(s)', '8(93)', 'Printed on 3/25/202']\n\n###\n\n", "completion": "END"}